Inflammatory breast cancer: Clinical progress and the main problems that must be addressed by Giordano, Sharon H & Hortobagyi, Gabriel N
284
ALND = axillary lymph node dissection; bFGF = basic fibroblast growth factor; FAC = 5-fluorouracil, doxorubicin, and cyclophosphamide; SL = sen-
tinel lymphadenectomy; VEGF = vascular endothelial growth factor.
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Introduction
Inflammatory breast cancer is a rare but aggressive
subtype of breast cancer, which historically was consid-
ered uniformly fatal. Treatment with local therapy, with
surgery, with radiation therapy, or with both resulted in few
long-term survivors. However, the advent of combined
modality therapy has resulted in a marked improvement in
prognosis. With current therapy, approximately one-third
of women diagnosed with inflammatory breast cancer will
become long-term survivors. This article reviews the clini-
cal characteristics of inflammatory carcinoma of the breast
and the clinical progress that has been made in the treat-
ment of this disease.
Inflammatory breast cancer accounts for about 5% of all
cases of breast cancer [1]. In general, women with inflam-
matory breast cancer present at a younger age, are more
likely to have metastatic disease at diagnosis, and have
shorter survival than women with non-inflammatory breast
cancer [1]. According to the latest revision of the Ameri-
can Joint Committee on Cancer staging guidelines, inflam-
matory carcinoma is classified at T4d, which makes all
patients with inflammatory carcinoma stage IIIB, IIIC, or IV
depending on the nodal status and presence of distant
metastases [2].
Clinical and pathological characteristics
Clinically, inflammatory breast cancer is characterized by
the rapid onset of breast warmth, erythema, and edema
(peau d’orange) often without a well-defined mass.
Along with extensive breast involvement, women with
inflammatory carcinoma often have early involvement of
the axillary lymph nodes. Taylor and Meltzer provided a
classic description of inflammatory breast cancer in their
1938 paper: “The redness, which may vary from a faint
blush to a flaming red, spreads diffusely over the breast,
which becomes hot, pitted, and edematous, presenting
an ‘orange-skin’ appearance. Meanwhile the cancer
spreads rapidly throughout the entire breast in the form
of a diffuse ill-defined induration. The breast may swell to
two or three times its original volume within a few
weeks” [3]. The rapidity of growth can be used to distin-
guish true ‘primary’ inflammatory carcinoma from
neglected locally advanced breast tumors that have
developed inflammatory features (‘secondary’ inflamma-
tory carcinomas) [3]. The mammographic appearance of
inflammatory breast cancer differs from other breast
tumors because less than half will show a discrete mass
[4,5]. However, other abnormal findings such as skin
thickening, trabecular thickening, and axillary adenopathy
are present in the majority of patients [5]. Figure 1
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Inflammatory breast cancer is a rare but highly aggressive form of locally advanced breast cancer.
Historically, this disease was uniformly fatal; however, with the advent of induction chemotherapy and
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shows the typical clinical and radiographic appearance
of inflammatory breast carcinoma.
Inflammatory breast carcinoma is not associated with a
particular histologic subtype and can occur in association
with infiltrating ductal or lobular, small cell, medullary, and
large cell carcinomas [6]. The characteristic pathologic
finding is dermal lymphatic invasion by carcinoma, which
can lead to obstruction of the lymphatic drainage causing
the clinical picture of erythema and edema. However, the
diagnosis of inflammatory carcinoma is made on clinical
grounds, and the absence of dermal lymphatic invasion
does not exclude the diagnosis. Patients with the clinical
features of inflammatory carcinoma should be treated
aggressively even if they do not have pathologic evidence
of dermal lymphatic invasion.
The most significant prognostic factor for women with
inflammatory breast cancer is the presence of lymph node
involvement. Patients with lymph node involvement have
shorter disease-free and overall survival than patients with
node-negative disease [7,8]. Extensive erythema, the
absence of estrogen receptor, and the presence of muta-
tions in the p53 gene have also been associated with
poorer outcomes in patients with inflammatory carcinoma
of the breast [7–9]. Because most women with inflamma-
tory carcinoma do not have discrete masses, tumor size
does not have the same prognostic value as in women
with non-inflammatory carcinoma.
Inflammatory carcinoma of the breast has distinct biolog-
ical characteristics that differentiate it from non-inflam-
matory carcinoma. These tumors more often have a high
S-phase fraction, are high-grade, are aneuploid, and lack
hormone receptor expression [6,10,11]. Paradiso and
colleagues found that 44% of inflammatory breast
cancers were estrogen-receptor-positive and 30% were
progesterone-receptor-positive compared with 64% and
51%, respectively, in patients with locally advanced, non-
inflammatory breast cancer [10]. In addition, inflamma-
tory carcinomas are more likely to have mutations in p53.
In a study of prognostic markers in inflammatory breast
cancer, Aziz and colleagues compared 40 cases of
inflammatory breast cancer with 80 controls matched by
patient age and tumor grade, and showed that inflamma-
tory breast cancers were more likely to overexpress p53
(69% versus 48%) [11]. The normal function of p53 can
be altered by two distinct mechanisms in inflammatory
breast cancer: direct mutation (30%) or by cytoplasmic
sequestration of the protein (37%) [12]. The data
regarding the role of c-erbB-2 overexpression in inflam-
matory breast cancer have been more variable, but most
studies have found no difference in the rates of c-erbB-2
overexpression between inflammatory and non-inflamma-
tory carcinomas of the breast [11,13]. Similarly, no differ-
ence has been seen in the frequency of expression of
EGFR and cathepsin D between inflammatory and non-
inflammatory cancers [11].
In addition to having different rates of expression of many
standard prognostic markers, inflammatory breast cancers
can also be differentiated by their highly angiogenic and
vascular characteristics. In a study of 67 tumor specimens,
McCarthy and colleagues reported that inflammatory breast
cancers have significantly higher microvessel density [14].
Merajver and colleagues have found that inflammatory carci-
noma cells are more likely to have high levels of vascular
endothelial growth factor (VEGF) and basic fibroblast
growth factor (bFGF) [15]. The authors propose that the
high levels of members of the VEGF family might account
for tumor neovascularization and the lymphotactic process
in inflammatory breast cancer. Inflammatory breast cancers
might also be more likely to express E-cadherin, a trans-
membrane glycoprotein that mediates cell–cell adhesion,
and may contribute to the aggressive lymphovascular inva-
sion seen in inflammatory cancers [16]. Kleer and col-
leagues reported that 100% (20 of 20) inflammatory
carcinomas expressed E-cadherin, compared with 68% (15
of 22) of non-inflammatory breast tumors [17]. Alpaugh and
colleagues developed a human xenograft model of inflam-
matory breast cancer (MARY-X), and the investigators
detected a 10–20-fold overexpression of E-cadherin in the
xenograft [18]. Another human inflammatory breast cancer
xenograft (WIBC-9) was developed by Shirakawa and col-
leagues [19]. This xenograft showed overexpression of
angiogenic factors, including VEGF, bFGF, and Flt-1, which
could be potential therapeutic targets [19].
Several genes have been identified that might contribute to
the aggressive clinical behavior of inflammatory breast
cancer. Van Golen and colleagues reported that the overex-
pression of RhoC GTPase and the loss of expression of
LIBC (lost in inflammatory breast cancer) were highly corre-
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lated with an inflammatory carcinoma phenotype [20].
LIBC, a novel gene, was lost in 80% of inflammatory speci-
mens in comparison with 21% of noninflammatory tumors.
RhoC GTPase, a gene involved in cytoskeletal reorganiza-
tion, was overexpressed in 90% of inflammatory tumors in
comparison with 38% of non-inflammatory cancers. Further-
more, when a stable RhoC transfectant cell line was
created, RhoC behaved as a transforming oncogene con-
ferring a highly invasive phenotype similar to that seen in
inflammatory breast cancer [21]. These genes remain a
promising avenue for future investigation.
Therapy
Historically, patients with inflammatory breast carcinoma
who were treated with surgery alone have had very poor
outcomes, and most surgeons have considered the diag-
nosis a contraindication to surgery. Similarly, local therapy
with radiation or with a combination of radiation and
surgery resulted in virtually no long-term survivors [6].
However, the development of active chemotherapy regi-
mens, used in combination with local therapy, has resulted
in a marked improvement in prognosis for patients with this
aggressive form of breast cancer. Our first report demon-
strated that two-thirds of patients with inflammatory breast
cancer responded to induction FAC (5-fluorouracil, doxoru-
bicin, and cyclophosphamide), and 50% and 31% of those
treated with FAC, radiotherapy, and then adjuvant
chemotherapy remained relapse-free 2 and 5 years after
diagnosis, respectively [22]. Most series have reported that
at least one-third of patients treated with combined modal-
ity therapy are alive at 5 years [6].
An update of experience at the MD Anderson Cancer
Center with inflammatory breast cancer over the past
20 years was published by Ueno and colleagues [4]. A total
of 178 patients were treated with combined modality
therapy, which consisted of doxorubicin-based induction
chemotherapy, local therapy with radiotherapy with or
without mastectomy, and adjuvant chemotherapy. In this
series, 28% of patients were alive and without evidence of
disease beyond 15 years. Overall survival was 40% at
5 years and 33% at 10 years, with a median survival of
37 months. Other large series of patients with inflammatory
breast cancer treated with combined modality therapy have
reported similar survival rates, demonstrating the change in
natural history of inflammatory breast cancer since the
advent of induction chemotherapy [23,24].
The treatment of inflammatory breast cancer requires
careful coordination of care between the medical, surgical,
and radiation oncologists because most patients will be
treated with a combination of these therapeutic modalities.
The initial component of therapy should be induction
chemotherapy (Fig.2). Many different regimens have been
used, most of which are anthracycline-based. Ueno and
colleagues found that 71% of all patients had a response
to anthracycline-based induction chemotherapy, with 12%
of patients achieving a complete response [4]. In addition,
initial response to induction chemotherapy was an impor-
tant predictor of survival; disease-free survival at 15 years
was 44% in patients who had a complete response to
induction chemotherapy, 31% in those who had a partial
response, and 7% in patients who did not respond to
therapy. A study from the Centre H Becquerel showed
that dose-intense therapy resulted in higher response
rates, but these high response rates did not translate into
improved survival [25].
After induction chemotherapy, patients should proceed
with definitive local therapy with radiation, surgery, or both.
Considerable controversy still exists as to the optimal local
treatment. This disease was traditionally considered inop-
erable because of the uniformly poor prognosis; however,
survival has improved with the use of chemotherapy, and
the role of surgery has been reexamined. Unfortunately,
many of the studies that have examined the role of mastec-
Figure 2
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tomy after induction chemotherapy have been difficult to
interpret because patients who have more limited disease
and those who have responses to therapy have been more
likely to have mastectomies. In addition, the rarity of this
disease precludes large randomized trials. The data
regarding mastectomy in inflammatory breast cancer are
conflicting: several trials have shown a benefit [26,27] but
others suggest that mastectomy offers no survival advan-
tage [28,29]. Fleming and colleagues reviewed the experi-
ence with mastectomy in 178 patients treated at the MD
Anderson Cancer Center [26]. The authors found that
patients who had a response to induction chemotherapy
benefited from the addition of mastectomy to chemother-
apy and radiation. These patients had significantly lower
rates of local recurrence and improved disease-specific
survival than patients who responded to induction
chemotherapy but did not undergo mastectomy.
A study by Curcio and colleagues of 90 patients with
inflammatory breast cancer reported a striking increase in
overall survival and decrease in local recurrence in
patients who had a mastectomy and were able to achieve
negative surgical margins [27]. This report suggests that if
negative surgical margins are obtainable, mastectomy
could be of benefit in patients with inflammatory breast
carcinoma. However, other studies have found survival to
be similar in patients who underwent mastectomy with
adjuvant radiation and in those who had radiation alone
[28,29]. Because the existing published data are conflict-
ing, radiation alone and mastectomy followed by radiation
remain reasonable treatment alternatives for local therapy.
For patients who are treated with mastectomy, the data
suggest that sentinel lymphadenectomy (SL) is not reliable
in predicting axillary staging. Stearns and colleagues
reported on the accuracy of sentinel lymph node biopsy
after neoadjuvant chemotherapy in a cohort that included
eight patients with inflammatory breast cancer [30]. Of the
eight patients with inflammatory breast cancer, three had
positive nodes on both axillary lymph node dissection
(ALND) and SL, one had negative nodes on both ALND
and SL, two had positive nodes on ALND that were
missed by SL, and two patients had non-identifiable sen-
tinel nodes. This study suggests that patients with inflam-
matory carcinoma who are being treated with mastectomy
should have standard ALND and not SL. However, the
limited experience with this diagnostic approach indicates
that additional evaluation is required.
Even after induction chemotherapy and local therapy, the
rates of relapse remain very high. Thus, we would recom-
mend further adjuvant chemotherapy with either an anthra-
cycline or a taxane after local treatment. Finally, patients
with estrogen or progesterone receptor-positive tumours
should receive 5 years of adjuvant hormonal therapy with
either tamoxifen or anastrazole. The role of high-dose
chemotherapy followed by autologous stem cell transplan-
tation remains experimental. Some studies have shown
encouraging results, but the patient populations were
highly selected and further trials are clearly needed before
transplantation can be recommended outside the context
of a clinical trial.
Conclusion
Despite the significant progress that has been made in the
treatment of this aggressive form of breast cancer, most
women with inflammatory breast cancer will relapse and
succumb to this disease. Clearly, further advances are
needed to improve the prognoses of women with inflam-
matory carcinoma. Current research on the biologic char-
acteristics of inflammatory carcinoma has made significant
strides in the understanding of the aggressive behavior of
this tumor, and future research will be vital in developing
targeted therapies. RhoC is a promising target for therapy;
recent reports have shown that farnesyl transferase
inhibitors have activity in reversing the invasive phenotype
of RhoC-overexpressing cell lines [31]. Other potential
targets for therapy include angiogenic factors, such as
VEGF, bFGF, or Flt-1, and overexpressed E-cadherin. As
our knowledge of the biology of inflammatory breast
cancer grows, other potential targets will emerge; these
scientific discoveries must be explored through ongoing
innovative clinical trials. Only through continued research
will we make progress in the treatment of this deadly form
of breast cancer.
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